spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Isotechnika 

 HSMN NewsFeed - 27 Dec 2012
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jul 2010
Lux Biosciences Names Dean Mitchell President and CEO
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 19 Oct 2009
Lux Biosciences Completes $50 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 19 May 2009
Emisphere Technologies Appoints Franklin M. Berger to Its Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 7 May 2009
Paladin Labs and Isotechnika Inc. Form Partnership for Commercialization of Voclosporin
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2009
Isotechnika Announces Full Enrollment Achieved in Partner Atrium's CONFIRM 1 Trial for Voclosporin Coated Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Jun 2008
Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 29 May 2008
Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2007
Isotechnika Inc. appoints two new senior company officers
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Isotechnika Inc. announces senior management changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Aug 2007
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 31 Jul 2007
EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences' LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 15 Jan 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 28 Nov 2006
Lux Biosciences Receives FDA Clearance for LX211 IND
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 4 Oct 2006
Isotechnika receives No Objection Letter from Health Canada for second Phase III psoriasis clinical trial
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 May 2006
Lux Biosciences Raises $36 Million in Series A Financing and Signs Agreement for Advanced Clinical Stage Product
Biopharmaceuticals Venture Capital Licensing
 HSMN NewsFeed - 25 May 2006
Isotechnika signs agreement granting Lux Biosciences Worldwide Ophthalmic rights to ISA247
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
Isotechnika
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.